

CLAIMS

1. A combination comprising:
 - i) a first component selected from the group consisting of:
 - a) a polypeptide comprising SEQ ID NO: 1, wherein the polypeptide substantially preserves the tumor suppressor activity of Omomyc, can dimerize with Myc and/or its obligate partner p21/p22 Max and inhibit Myc activity, is capable of translocating across the cell membrane and across the nuclear envelope,
 - b) a conjugate comprising a polypeptide comprising SEQ ID NO: 1 and a chemical moiety that facilitates cellular uptake of the polypeptide, wherein the conjugate substantially preserves the tumor suppressor activity of Omomyc, can dimerize with Myc and/or its obligate partner p21/p22Max and inhibit Myc activity, is capable of translocating across the cell membrane and across the nuclear envelope; and
 - ii) a second component that is an immuno-oncology agent, wherein the immuno-oncology agent is a PD-1 antagonist or a CTLA-4 antagonist selected from the group consisting of an anti-PD-1 antagonistic antibody, and an anti-CTLA-4 antagonistic antibody.
2. The combination according to claim 1, wherein the polypeptide is SEQ ID NO: 4.
3. The combination according to any one of claims 1 or 2, wherein the chemical moiety that facilitates the cellular uptake of the polypeptide is a cell-penetrating peptide sequence and wherein said cell penetrating peptide sequence and said polypeptide form a fusion protein.
4. The combination according to claim 3, wherein the cell-penetrating peptide sequence is selected from the group consisting of GRKKRRQRRR (SEQ ID NO: 37) and RRRRRRLR (SEQ ID NO: 38).
5. The combination according to any one of claims 1 to 4, wherein the conjugate additionally comprises a further nuclear localization signal.

6. The combination according to any one of claims 1 to 5, wherein the antagonistic antibody is pembrolizumab.
- 5
7. The combination according to any one of claims 1 to 6, wherein the first component is a polypeptide comprising SEQ ID NO: 1.
8. A pharmaceutical composition comprising a pharmaceutically effective amount of a
- 10 combination according to any one of claims 1 to 7 and a pharmaceutically acceptable excipient.
9. A combination according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8 for use in medicine.
- 15
10. Use of a combination according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8 in the manufacture of a medicament for the treatment of cancer.
- 20
11. The use according to claim 10, wherein the cancer is lung cancer.
12. The use according to any one of claims 10 or 11, wherein the composition is to be administered systemically or intranasally.
- 25
13. The use according to claim 12, wherein the intranasal administration is to be performed by instillation or nasal inhalation.
14. The use according to any one of claims 10 or 11, wherein the first component is to be administered intranasally or intravenously and the second component is to be
- 30 administered systemically.
15. The use according to any one of claims 10 to 14, wherein the polypeptide or the conjugate, synergistically interacts with the immuno-oncology agent in treating cancer.
- 35